A Smart Approach for Delivery of Nanosized Phenytoin using Biomaterial Isolated from Fragaria ananassa

Abstract

Objectives: The bionanosuspension was prepared by using the isolated biopolymer from Fragaria ananassa fruit which serve as a potential, natural polymeric nature biomaterial. The isolated biomaterial was used for the preparation of nanosized phenytoin loaded bionanoparticles in the form of bionanosuspension. The isolated biopolymer was characterized for its polymeric properties and its potentiality was evaluated in the delivery of nanosized phenytoin. Materials and Methods: The isolated biopolymer from Fragaria ananassa was used for the formulation of phenytoin loaded bionanosuspension. The sonication method was used for the preparation of bionanosuspension having bionanoparticles in nano range loaded with nanosized phenytoin. The accurate quantity of phenytoin and isolated biopolymer was mixed with other excipients like dextrose as nanosizent, polyvinyl alcohol, sodium benzoate with double distilled water and then sonicated in bath sonicator for 15 cycles (1cycle=3min). Results: The isolated biopolymer was characterized for DSC, FTIR, NMR, Mass and Zeta particle size analysis. The obtained results confirm its polymeric nature in different analysis. The prepared bionanoparticles showed the release of phenytoin in sustained manner over 36 hr. The release kinetic study was done by using the BIT-SOFT 1.12 software and t50% and t80%, r 2 were calculated. The formulation PF4 was found to be the best formulation having t50% of 17 hr and t80% of 28 hr with r 2 value of 0.9912. The best formulation PF4 showed up to 90.64% drug release over 36 hr. According to the release kinetic study the best fit model was found to be Korsmeyer-Peppas and the mechanism of drug release was found to be anomalous transport. Conclusion: Thus the isolated biopolymer from fruit pulp of Fragaria ananassa can be safely used for the preparation of nanosized phenytoin loaded bionanoparticles in the delivery of phenytoin in significant amount for the treatment of epilepsy.